# US 2025/0049766 A1 · High dosage tebipenem pivoxil tablet formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049766 A1
- Document ID: US20250049766A1
- Status: Published application
- Kind: A1
- Application number: 18/665,330
- Filed: 2024-05-15
- Published: 2025-02-13
- Earliest claimed: 2020-11-11
- Assignees: Spero Therapeutics, Inc.
- Applicants: Spero Therapeutics, Inc.
- Inventors: Akash Jain; Ching-Kuo Jim Chow
- Web page: https://patentgrep.com/patent/US20250049766A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

## Claims

### Claim 1

A tebipenem pivoxil HBr tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr,
15-25% w/w of a binder/diluent, wherein the binder/diluent is microcrystalline cellulose;
0.5 to 5% w/w of a disintegrant, wherein the disintegrant is crospovidone;
0.5 to 2% w/w of a glidant, wherein the glidant is silicon dioxide; and
0.5 to 5% w/w of magnesium stearate.

### Claim 2 (depends on 1)

The tebipenem pivoxil HBr tablet core of claim 1, comprising at least 75% w/w tebipenem pivoxil HBr.

### Claim at position 3

3-11. (canceled)

### Claim 12 (depends on 1)

The tebipenem pivoxil HBr tablet core of claim 1, comprising
15-25% w/w of microcrystalline cellulose, grade PH101;
0.5 to 5% w/w of crospovidone XL-10;
0.5 to 2.0% w/w of colloidal silicon dioxide, grade 200; and
0.5 to 5% w/w of magnesium stearate.

### Claim 13 (depends on 1)

The tebipenem pivoxil HBr tablet core of claim 1, wherein the fraction of tebipenem pivoxil HBr particles less than 45 μm is between 18% and 42%.

### Claim 14 (depends on 1)

The tebipenem pivoxil HBr tablet core of claim 1, exhibiting greater than 90% dissolution in less than 5 minutes in 500 ml pH 5 aqueous buffered medium, 37±0.5° C., at paddle speed 50 rpm

### Claim 15 (depends on 1)

A tebipenem pivoxil HBr tablet comprising the tablet core of claim 1 coated with an immediate release coating.

### Claim 16 (depends on 15)

The tablet of claim 15, wherein the immediate release coating comprises
hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), nethylcellulose (MC), sodium carboxymethyl cellulose (NaCMC), polyvinylpyrrolidone (PVP), a polyvinyl pyrrolidone-polyvinyl acetate coplymer, polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol copolymer, an acrylic coating, an acrylic acid ester, a methacrylic acid ester, or polyethylene glycol (PEG).

### Claim 17 (depends on 15)

The tablet of claim 15, wherein the tablet contains 300 mg tebipenem pivoxil (as tebipenem pivoxil HBr) and has a total weight of less than 500 mg.

### Claim 18 (depends on 1)

A method of treating a bacterial infection or nontuberculous mycobacterial infection in a patient, comprising administering a tebipenem pivoxil HBr tablet comprising the tablet core claim 1 to the patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient is a human.

### Claim 20 (depends on 19)

The method of claim 19 wherein the method is a method of treating a bacterial infection and the bacterial infection is a urinary tract infection.

### Claim 21 (depends on 18)

The method of claim 18, wherein the bacterial infection is a Gram-negative bacterial infection.

### Claim 22 (depends on 21)

The method of claim 21 wherein the Gram-negative infection is an E. coli infection, a Klebsiella pneumoniae infection, an Acinetobacter baumannii infection, a Citrobacter infection, an Enterobacter aerogenes infection, an Enterobacter cloacae infection, a Proteus mirabilis infection, a Pseudomonas aeruginosa, a Neisseria gonorrhoeae infection, a Serratia infection, or a Yersinia pestis infection.

### Claim 23 (depends on 18)

The method of claim 18, wherein the method is a method of treating a nontuberculous mycobacterial infection and the mycobacterial infection is a M. fortuitum, M. chelonae-abscessus, M. avium complex (MAC), M. abscessus, M. intracellulare, M. ulcerans, M. leprae, M. chimaera, M. paratuberculosis, M. parascrofulaceum, M. kansasii, M. marinum, M. simiae, or M. scrofulaceum infection.

### Claim 24 (depends on 1)

The tebipenem pivoxil HBr tablet core of claim 1, wherein the tablet core comprises tebipenem pivoxil HBr crystalline Form B.

### Claim at position 17

25-26. (canceled)

### Claim 27 (depends on 24)

A method of treating a cUTI, acute pyelonephritis, or bacteremia in a patient comprising administering a tablet comprising the tablet core of claim 24 to the patient.

### Claim 28 (depends on 27)

The method of claims 27, wherein the tablet core comprises 300 mg to 800 mg tebipenem pivoxil (by weight of free base) and is administration is 3 times per day for at least 3 days.

### Claim 29 (depends on 27)

The method of claim 27, wherein the patient has renal impairment with creatine clearance <20 mL/min., end-stage renal disease (ESRD), or is receiving hemodialysis (HD) one or more times per week, wherein the tablet core comprises 300 mg tebipenem pivoxil (by weight of free base) and is administration is 2 or 3 times per day for at least 3 days.

### Claim 30 (depends on 18)

The method of claim 18, wherein the bacterial infection is a Gram-positive bacterial infection.

### Claim 31 (depends on 30)

The method of claim 30 wherein the Gram-positive infection is an Staphylococcus aureus infection, a Staphylococcus epidermidis infection, a Staphylococcus saprophyticus infection, an Enterococcus faecium infection, a Staphylococcus lugdunensis infection, an Enterococcus hirae infection, a Streptococcus gallolyticus bacterium infection, or an Enterococcus faecalis infection.
